American Cardiology of Cardiology / American Heart Association
|
20073838 Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of ACC/AHA. Tas Force on Practice Guidelines (Writing Committee to Revise the 2002 unstable angina non st-elevation myocardial infarction. Circulation. 2007;116(7):e148-304.
|
Recomendação de fazer o pré-tratamento, embora apresente também a seguinte frase: "Iniciação do clopidogrel pode ser postergada até haver definição sobre revascularização |
20124141 Ineid H, Anderson JL, Wright RS, Adams CD, Bridge CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina non-ST elevation myocardial infarction (updating the 2007 Guideline and Replacing the 2011 Focused Update) a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation.2012;126(7):875-910.
|
Diagnóstico definido de SCASST de risco médio e alto deve receber dupla antiagregação na apresentação (pré-cateterismo) |
20141212 Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiatis TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the management of patients with non ST-elevation acute coronary syndromes: a report of the ACC/AHA Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-426. Erratum in: Circulation. 2014;130(25):e433-4.
|
Não faz recomendação clara para DAPT antes de conhecer anatomia e recomenda ataque de inibidor P2Y12 antes, naqueles que serão submetidos à ICP com stent |
20073939 Bassand JP, Hamm CW, Ardissino D, Boersma E, Budai A, Fernandes-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Eur Heart J. 2007;28(13):1598-660.
|
"Postergar o clopidogrel para usar após a angiografia não pode ser recomendado" |
20104040 Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31(20):2501-55.
|
|
20114343 Hamm CW, Bassant JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054.
|
Uso de um inibidor de P2Y12 o mais breve possível" |
European Society of Cardiology
|
20144444 Kolh P, Windecker S, Alfonso F, Collet P, Cremer J, Falk V, et al; Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS guidelines on myocardial revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Intervention (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-92.
|
Pré-tratamento com prasugrel em pacientes cuja anatomia coronária não é conhecida é classe III, Nível de Evidência B
|
20151313 Roffi M, Patrono C, Collet JP, Mueller C, Vahimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2015 Aug 29. [Epub ahead of print].
|
Há uma seção específica para discutir o momento de administrar o inibidor P2Y12, na qual se expõe que se trata de um tema controverso e que, por não exisitr uma investigação adequada com clopidogrel e ticagrelor, a diretriz não formulou nenhuma recomendação a favor ou contra pré-tratamento na estratégia invasiva precoce, exceto para prasugrel, que não se deve fazer pré-tratamento. Se manejo conservador, deve-se iniciar inibidor P2Y12 (preferencialmente ticagrelor) assim que o diagnóstico for confirmado |
Sociedade Brasileira de Cardiologia |
20133737 Nicolau JC, Timerman A, Marin-Neto JA, Piegas LS, Barbosa CJ, Franci A, et al; Sociedade Brasileira de Cardiologia. Use of demonstrably effective therapies in the treatment of acute coronary syndromes: comparison between different Brazilian regions. Analysis of the Brazilian Registry on Acute Coronary Syndromes (BRACE). Arq Bras Cardiol.2012;98(4):282-9.
|
Em ambas não há recomendação formal específica sobre o momento do segundo antiplaquetário, mas indica usar prasugrel só após conhecer anatomia coronária |
20144242 Lorga Filho AM, Azmus AD, Soeiro AM, Quadros AS, Avezum Jr A, Marques AC, et al. Brazilian guidellines on platelet antiaggregants and anticoagulants in cardiology. Arq Bras Cardiol. 2013;101(3 Suppl 3):1-95.
|